Thyroid-stimulating antibody is related to Graves' ophthalmopathy, but thyrotropin-binding inhibitor immunoglobulin is related to hyperthyroidism in patients with Graves' disease.

We investigated the relationship between thyroid function or ophthalmopathy of Graves' disease and thyrotropin receptor antibodies (TRAb) in 155 untreated patients with Graves' hyperthyroidism. All patients were examined by ophthalmologists, and underwent computed tomography of the orbit and measurement of serum free triiodothyronine (FT3), free thyroxine (FT4), thyrotropin-binding inhibitor immunoglobulin (TBII), and thyroid stimulating antibodies (TSAb). Patients were divided into three groups according to the presence of orbital fat increase (OFI) and extraocular muscle enlargement (EME): 57 patients without OFI and EMO formed the no Graves' ophthalmopathy (NGO) group; 55 patients with OFI but without EMO formed the OF group; 43 patients with EME with or without OFI formed the EM group. The FT3, FT4, and thyroid weight increased in the order of the EME, NGO, and OFI groups. TSAb increased in the order of the NGO, OFI, and EME groups, and TSAb was significantly greater in the EME and OFI than in the NGO group. TBII was not significantly different among the three groups, but was lower in EME than NGO. There was a significant positive correlation between TBII and FT3 or FT4 in all patients combined as well as in all three groups, but correlation between TSAb and FT3 or FT4 was very weak in all groups, and that between TSAb and FT3 was not significant in the EM group In the relationship between ophthalmopathy and TRAb, the sum of the scores of eyelid swelling, proptosis, and extraocular muscle enlargement was taken as a measure of the overall severity of the Graves' ophthalmopathy (GO). TSAb was significantly correlated with the GO score, but there was no correlation between TBII and GO scores. In conclusion, TSAb was correlated with ophthalmopathy but TBII was related to hyperthyroidism.

[1]  K. Usadel,et al.  Glycosylation variants of human TSH selectively activate signal transduction pathways , 1997, Molecular and Cellular Endocrinology.

[2]  Y. Inoue,et al.  Localization and clinical significance of thyrotropin receptor mRNA expression in orbital fat and eye muscle tissues from patients with thyroid-associated ophthalmopathy. , 1996, Thyroid : official journal of the American Thyroid Association.

[3]  A. Heufelder,et al.  Detection of TSH receptor RNA in cultured fibroblasts from patients with Graves' ophthalmopathy and pretibial dermopathy. , 1993, Thyroid : official journal of the American Thyroid Association.

[4]  B. Frueh.  Why the NOSPECS classification of Graves' eye disease should be abandoned, with suggestions for the characterization of this disease. , 1992, Thyroid : official journal of the American Thyroid Association.

[5]  P. Rocmans,et al.  Unlike thyrotropin, thyroid-stimulating antibodies do not activate phospholipase C in human thyroid slices. , 1991, The Journal of clinical investigation.

[6]  C. Gorman,et al.  Diagnosis and Management of Graves' Ophthalmopathy , 1990 .

[7]  K. M. Huang,et al.  CORRELATION OF ORBITAL COMPUTED TOMOGRAPHY AND ANTIBODIES IN PATIENTS WITH HYPERTHYROID Graves'DISEASE , 1990, Clinical endocrinology.

[8]  R. Utiger.  Treatment of Graves' ophthalmopathy. , 1989, The New England journal of medicine.

[9]  D. Emrich,et al.  TSH BINDING‐INHIBITING ANTIBODIES IN HYPERTHYROIDISM: RELATIONSHIP TO CLINICAL SIGNS AND HORMONE LEVELS , 1989, Clinical endocrinology.

[10]  Y. Iwatani,et al.  Improvement of infiltrative ophthalmopathy in parallel with decrease of thyroid-stimulating antibody (TSAb) activity in two patients with hypothyroid Graves’ disease , 1989, Journal of endocrinological investigation.

[11]  H. Hatabu,et al.  STUDIES ON THYROTROPHIN RECEPTOR ANTIBODIES IN PATIENTS WITH EUTHYROID GRAVES' DISEASE , 1988, Clinical endocrinology.

[12]  J. How,et al.  A thyroid cytotoxic antibody that cross-reacts with an eye muscle cell surface antigen may be the cause of thyroid-associated ophthalmopathy. , 1988, The Journal of clinical endocrinology and metabolism.

[13]  I. Hay,et al.  Clinical utility of thyrotropin-receptor antibody assays: comparison of radioreceptor and bioassay methods. , 1988, Mayo Clinic proceedings.

[14]  B. Glaser,et al.  Bioassay of thyroid-stimulating immunoglobulin in cryopreserved human thyroid cells: optimization and clinical evaluation. , 1988, Clinical chemistry.

[15]  J. Mckenzie,et al.  Pregnancy-associated changes in the thyroid-stimulating antibody of Graves' disease and the relationship to neonatal hyperthyroidism. , 1983, The Journal of clinical endocrinology and metabolism.

[16]  L. Braverman,et al.  THYROID BINDING ANTIBODIES AND OTHER IMMUNOLOGICAL ABNORMALITIES IN PATIENTS WITH GRAVES’OPHTHALMOPATHY: EFFECT OF TREATMENT WITH CYCLOPHOSPHAMIDE , 1979, Clinical endocrinology.

[17]  D. Evered,et al.  THYROID‐STIMULATING IMMUNOGLOBULINS IN OPHTHALMIC GRAVES'DISEASE , 1977, Clinical endocrinology.

[18]  D. Adams,et al.  Stimulation of the human thyroid by infusions of plasma containing LATS protector. , 1974, The Journal of clinical endocrinology and metabolism.